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Abstract
Introduction Since the prostate-specific membrane antigen
(PSMA) is frequently over-expressed in prostate cancer
(PCa) several PSMA-targeting molecules are under develop-
ment to detect and treat metastatic castration resistant prostate
cancer (mCRPC). We investigated the tissue kinetics of a
small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-
5-(3-(4-[124I]iodophenyl)ureido)pentyl)ureido)pentanedioica-
cid; MIP-1095) using PET/CT to estimate radiation dosimetry
for the potential therapeutic use of 131I-MIP-1095 in men with
mCRPC. We also report preliminary safety and efficacy of the
first 28 consecutive patients treated under a compassionate-
use protocol with a single cycle of 131I-MIP-1095.
Methods Sixteen patients with known prostate cancer
underwent PET/CT imaging after i.v. administration of 124I-
MIP-1095 (mean activity: 67.4 MBq). Each patient was
scanned using PET/CT up to five times at 1, 4, 24, 48 and
72 h post injection. Volumes of interest were defined for tumor
lesions and normal organs at each time point followed by dose
calculations using the OLINDA/EXM software. Twenty-eight
men with mCRPC were treated with a single cycle of 131I-
MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and
followed for safety and efficacy. Baseline and follow up
examinations included a complete blood count, liver and
kidney function tests, and measurement of serum PSA.
Results I-124-MIP-1095 PET/CT images showed excellent
tumor uptake and moderate uptake in liver, proximal intestine
and within a few hours post-injection also in the kidneys. High
uptake values were observed only in salivary and lacrimal
glands. Dosimetry estimates for I-131-MIP-1095 revealed that
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the highest absorbed doses were delivered to the salivary
glands (3.8 mSv/MBq, liver (1.7 mSv/MBq) and kidneys
(1.4 mSv/MBq). The absorbed dose calculated for the red
marrow was 0.37 mSv/MBq. PSA values decreased by
>50 % in 60.7 % of the men treated. Of men with bone pain,
84.6 % showed complete or moderate reduction in pain.
Hematological toxicities were mild. Of men treated, 25 %
had a transient slight to moderate dry mouth. No adverse
effects on renal function were observed.
Conclusion Based on the biodistribution and dose calcula-
tions of the PSMA-targeted small molecule 124I-MIP-1095
therapy with the authentic analog 131I-MIP-1095 enables a
targeted tumor therapy with unprecedented doses delivered to
the tumor lesions. Involved lymph node and bone metastases
were exposed to estimated absorbed doses upwards of 300 Gy.
Keywords Prostatecancer .PSMAtargeting .Radioiodinated
PSMA ligand . Biodistribution . Absorbed dose estimates .
Dosimetry
Introduction
Surgery, radiation and cytotoxic drugs are the pillars of
treatment of oncological diseases. Generally, surgery and
radiation cannot be fundamentally improved in the case
of disseminated disease. The efficiency of systemic tu-
mor treatments is limited by the side effects of com-
monly used standard chemotherapeutics and, thus, the
resulting limited amount of the respective standard che-
motherapeutic is not sufficient for an effective treatment
of most solid tumors.
Once metastasized, prostate cancer becomes one of the
most aggressive types of tumors. It affects at least 2 million
men in the United States and 4 million men in Europe [1]
http://globocan.iarc.fr/factsheets/cancers/prostate2008 [2],
and most patients with metastatic castrate resistant prostate
cancer (mCRPC) will relapse due to inefficient treatment of
the primary lesion. [3]
During the past decade, new therapeutic options, such as
new anti-androgen therapies, systemic radiopharmaceuticals,
including radium-223 chloride, immunotherapeutics/vaccines
and second generation chemotherapeutics such as cabazitaxel,
were approved for mCRPC patients. Despite these develop-
ments, mCRPCwill claim the lives of more than 250,000 men
worldwide each year [4]. Alternative therapeutic options for
men with mCRPC are urgently needed.
There are two possibilities to extend the therapeutic win-
dow required to eradicate aggressive tumors: a) differential
action of the drug in the tumor cells and b) specific uptake of
the drug. Fortunately, prostate tumors specifically express the
prostate-specific membrane antigen (PSMA), an ideal target
for imaging and targeted systemic treatment of prostate
cancer.
PSMA, also known as folate hydrolase I or glutamate
carboxypeptidase II, is a 750-amino acid type II transmem-
brane glycoprotein primarily expressed in normal human
prostate epithelium. Since PSMA is over-expressed by virtu-
ally all prostate cancers, and its expression is further increased
in poorly differentiated, metastatic and hormone-refractory
carcinomas, it is an attractive target for diagnosis and staging
of prostate cancer as well as the delivery of endoradiotherapy
specifically to prostate cancer cells [5, 6].
Recently, radiolabeled monoclonal antibodies that bind to
the extracellular domain of PSMAwere shown to accumulate
in PSMA-positive prostate tumors in animals. Phase 1 and 2
clinical trials utilizing the PSMA monoclonal antibody J591,
radiolabeled with 90Y or 177Lu have shown promising early
results [7–11]. While radiolabeled monoclonal antibodies
hold promise for tumor detection and therapy, clinical suc-
cesses have been limited (with the exception of lymphoma) in
large part because these large molecules exhibit poor perme-
ability in solid tumors and slow clearance from the circulation.
This combination leads to suboptimal tumor targeting and an
increased absorbed dose to red marrow, narrowing the thera-
peutic window. Low molecular weight compounds, with
higher permeability into solid tumors, offer a significant ad-
vantage in achieving higher uptake per gram of tumor tissue
and a high percentage of specific binding. Furthermore, small
molecules display more rapid tissue distribution and faster
blood clearance, compared with intact immunoglobulins. The-
se properties often lead to enhanced target to non-target tissue
ratios which is important not just for imaging but also for
successful application of therapeutic absorbed doses.
Molecular Insight Pharmaceuticals, Inc. has developed
a series of 123I-labeled and 99mTc-labeled small mole-
cules for targeting the extracellular domain of prostate-
specific membrane antigen (PSMA), a target initially
selected for the diagnostic assessment of primary and
metastatic prostate cancer [12, 13]. The results of the
initial clinical investigation of 123I-MIP-1072 and 123I-
MIP-1095 led to the evaluation of these radioiodinated
ligands as potential PSMA-targeted radiotherapeutics
when radiolabeled with 131I [14, 15].
The outstanding tumor selectivity observed with these
compounds suggests the possibility of treatment efficacy that
may compete with the efficacies attained for other cancers
with highly specific drugs such as Gleevec [16]. Different
from the application of normal cytotoxic drugs, the possible
side effects of endoradiotherapeutics can be estimated by
dosimetric calculations for normal tissues.
In preparation for a therapeutic application of 131I-MIP-
1095 we performed PET/CT measurements with the authentic
analog 124I-MIP-1095 to obtain dosimetric data for normal
organs and assessed safety and efficacy of therapy with 131I-
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MIP-1095 under a compassionate-use protocol in 28 patients
with metastatic castrate resistant prostate cancer.
Methods
Radiopharmaceuticals
( S ) - 2 - ( 3 - ( ( S ) - 1 - C a r b o x y - 5 - ( 3 - ( 4 - [ 1 3 1 I ]
iodophenyl)ureido)pentyl)ureido)pentanedioic acid; 131I-
MIP-1095
The radioiodinatedcompound was prepared by
iododestannylation of the trimethylstannyl precursor (S)-di-
ter t-butyl 2-(3-((S ) -1- ter t-butoxy-1-oxo-6-(3-(4-
( t r i m e t h y l s t a n n y l ) p h e n y l ) u r e i d o ) - h e x a n e - 2 -
yl)ureido)pentanedioate, to form (S)-2-(3-((S)-1-carboxy-
5-(3-(4-[131I]iodophenyl)ureido)pentyl)ureido)pentanedioic
acid. [131I]NaI (approx. 7 GBq, GE Healthcare) was reacted
with 100 μL of a 250 μg/mL solution of (S)-di-tert-butyl
2 - ( 3 - ( ( S ) - 1 - t e r t - b u t o x y - 1 - o x o - 6 - ( 3 - ( 4 -
( t r i m e t h y l s t a n n y l ) p h e n y l ) u r e i d o ) h e x a n e - 2 -
yl)ureido)pentanedioate in ethanol and 50 μL of a freshly
prepared solution of 0.15 mL 30 % hydrogen peroxide in
0.85 mL acetic acid. The reaction mixture was diluted after
5 min with 1.5 mL of water and loaded onto a SOLA car-
tridge. The cartridge was washed with 2 mL of water to
remove unreacted radioiodide and inorganic and organic salts
and dried by a stream of nitrogen.
T h e (S ) - 2 - ( 3 - ( (S ) - 1 - c a r b ox y - 5 - ( 3 - ( 4 - [ 1 3 1 I ]
iodophenyl)ureido)pentyl)ureido)pentanedioic acid ester was
eluted from the dry column using 0.5 mL of neat
trifluoroacetic acid (TFA) and deprotected at room tempera-
ture for 15 min to cleave the tert-butyl ester protecting groups.
After the deprotection was complete, the solution was diluted
with water (5 mL) and trapped on a Plexa cartridge. The
cartridge was washed with 5 mL 20 % ethanol in water and
eluted with 1 mL of 100 % ethanol, wherein the solution was
passed through a GV sterile filter. The final solution was
diluted with 9 mL of sterile water and 200 μL phosphate
buffer concentrate to prepare the final formulation ma-
trix containing 10 % ethanol. The radioiodinated com-
pound was analyzed by HPLC on a Chromolith® Per-
formance RP-18e column (100×3 mm2) using a linear
gradient from 0 % to 100 % of acetonitrile in water
(both containing 0.1 % TFA) over 5 min. UV absor-
bance was detected at 214 nm. Radiochemical yields
ranged from 38 to 78 %, average radiochemical purity
was 97 %, and specific activity ranged from 1.5 to
6.4 mCi/μmol (55.5 to 236.8 MBq/μmol). A slightly
modified procedure to that described above was used
to prepare 124I-MIP-1095. 124I was purchased from
Eckert & Ziegler (Berlin, Germany).
Glu-NH-CO-NH-Lys(Ahx)-[68Ga]-HBED-CC
The PSMA-binding ligand Glu-NH-CO-NH-Lys(Ahx)-
HBED-CC was radiolabeled with gallium-68 and used pre-
and post-therapy for assessment of tumor burden in patients
undergoing 131I-MIP-1095 therapy. 68Ga-labeled Glu-NH-
CO-NH-Lys(Ahx)-HBED-CC was prepared as previously de-
scribed [17].
Dosimetry imaging and pharmacokinetics of 124I-MIP-1095
Sixteen patients underwent dosimetry scans as described in
the following paragraphs. All patients had histologically prov-
en prostate cancer – either by biopsy or by prostatectomy. The
patients had several different treatments in advance of our
exam. Eleven men had a radical prostatectomy, two received
brachytherapy, all patients received hormone ablation therapy,
nine received additional radiotherapy of the prostate and four
received radiotherapy elsewhere for their disease, and six had
prior chemotherapy. The median PSA value was 110.5 ng/ml
at the time of our scans (range 1.13 to 577 ng/dl). The median
age was 71.9 years (range 55.2 to 76.6 years). Median
Gleason score was 7 (range 6 to 9).
The patients were scheduled for PET/CT using 124I-MIP-
1095 in order to detect tumor lesions for staging in advance of
a possible PSMA-therapy. All patients gave their written
informed consent for the examination after extensive educa-
tion. The evaluation of the data was approved by the local
ethics committee (protocol number S-321/2012).
Depending on the efficiency of radiolabeling (range 26 to
105MBq, supplementary data Table A) the patients received a
median activity of 67 MBq (range 26 to 105 MBq) of 124I-
MIP-1095 intravenously followed by a saline flush with
10 mL of 0.9 % NaCl. The median of the patient weight was
77.5 kg (range 70 to 112.5 kg) resulting in a median activity of
0.87 MBq/kg body weight (range 0.27 to 1.4 MBq/kg bw).
PET/CT image acquisition
Serial PET/CT images were collected using a Siemens
Biograph 6 PET/CT system (Erlangen, Germany) for each
patient beginning approximately 1 h post-administration (pri-
or to voiding) and again at approximately 4, 24, 48, 72 and/or
96 h (Supplementary data Table A). A non-contrast-enhanced
CT scan was performed 1 h post tracer injection using the
following parameters: slice thickness of 5 mm; increments of
0.8 mm; soft tissue reconstruction kernel; 130 keV and
80 mAs. Immediately after CT scanning, a whole body PET
was acquired in 3D mode from head to toe in two serial
acquisitions at the initial time point and head to mid-thigh at
subsequent time points. Only head to mid-thigh acquisitions
were obtained at the initial time point in two of 16 patients.
For each bed position (16.2 cm, overlapping scale: 4.2 cm) we
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used 4 min. acquisition time with a 15.5 cm field of view
(FOV). Typically five PET time points were obtained for each
patient (n=13). In three cases only four (n=1) or three scans
(n=2) were available due to technical failure, logistical rea-
sons or claustrophobia of the patient.
The emission data were corrected for randoms, scatter and
decay. Reconstruction was conducted with an ordered subset
expectation maximization algorithm (OSEM) with four
iterations/eight subsets and Gauss-filtered to a transaxial res-
olution of 4.2 mm at FWHM (full width at half maximum).
Attenuation correctionwas performed using the low dose non-
enhanced computed tomography data. PET and CT were
performed using the same protocol for every patient on a
BIOGRAPH-6 PET/CT scanner (Siemens, Germany). No
additional manufacturer-supplied corrections for prompt gam-
ma coincidences were applied at the time of acquisition. Axial
slices were reconstructed with CT-based measured attenuation
correction and iterative ordered subsets expectations maximi-
zation (OSEM) algorithm.
Calibration of the PETactivity was performed by imaging a
volume of 124I measured in an ISOMED 1010 dose calibrator
(Dresden, Germany) to develop a calibration factor which
allows for correction of prompt gamma emissions and the
low positron fraction of 124I. We measured the activity of a
20 mL imaging standard containing a minimal amount of 124I-
MIP-1095 in advance of each PET/CT scan in the dose cali-
brator and set this syringe adjacent to the head of the patient
during the scan.
Image quantification
Volumes of interest (VOIs) were created from the sum of
adjacent transaxial regions of interest (ROIs) manually drawn
along the boundaries of a standard set of normal organs and
tissues, using CT as a guide, including salivary glands, brain,
heart, kidneys, liver, lungs, spleen, thyroid, muscle, abdomen,
tumor lesions and whole body. VOIs were created on the 4 h
time point and copied to all other time points for each patient
and repositioned if needed using the fused CT for proper
placement. Count activity for each volume was extracted
using a commercially available nuclear medicine workstation
(Hermes Medical Systems, Stockholm, Sweden).
Initial whole body count activity from head and mid-thigh
was summed with the mid-thigh to toe counts to determine
total body uptake immediately post-injection (1 h p.i. and
prior to voiding) and considered to be equal to 100 % of the
injected activity of 124I-MIP-1095. In two patients where leg
count data were not available, the initial head to mid-thigh
VOI count data were used leading to an increase in the
calculated percent of the injected activity in organ VOIs.
Hence, for two patients, the organ absorbed doses are biased
slightly higher.
All organ (and whole body) VOI data were divided by the
initial total body VOI value to obtain the fractional amount of
injected activity in each VOI/organ and corrected for radioac-
tive decay of 124I to the time of injection. The resulting decay
corrected estimates of factional activity distribution were used
in the biomodeling.
Source organ time-activity curve fitting (biomodeling)
Data describing the fraction of the injected activity in each
source organ were mathematically simulated. For this data set,
bi-exponential functions were iteratively fit to each source
organ time-activity curve using a nonlinear least-squares re-
gression algorithm (SAAM II v1.2 software; The SAAM
Institute, Inc., Seattle, Washington.www.saam.com). The
form of the bi-exponential equation, A(t), is given below:
A tð Þ ¼ a1e−λ1t þ a2e−λ2t
Where ai is the i
th fractional uptake and λi is its associated
biological removal rate (h-1). The residence time, τ, is obtain-
ed by analytically integrating the curve-fit equation, A(t) from
t=0 to infinity, after multiplying each term by the physical
decay term (i.e., e−λP t ). The effective removal rate is the sum
of the biological removal rate and the physical decay rate of
the nuclide. One patient had three images and hence a set of
mono-exponentials was used in that patient’s biomodeling.
The source organ residence times were calculated for 124I
and 131I, as described above, using each radionuclide’s respec-
tive physical half-life. Implicit is the assumption that changing
radioiodine from isotope 124I to isotope 131I does not alter the
compound’s biodistribution or kinetics.
Excretory clearance and total body residence times
Urinary clearance was estimated from the whole body image
data. The whole body time-activity curve was fit to a bi-
exponential function. The whole (total) body residence time
was calculated by integrating the whole body time activity
curve fit equation, after subtracting the estimated fecal excre-
tion fraction from the slower clearing component of the whole
body time activity curve. Integration of this “corrected”whole
body retention function yielded the corrected whole body
residence time. The parameters (fraction and associated bio-
logical removal half-time) of the corrected whole body time
activity curve were used as input data for the dynamic
(urinary) bladder model. The urinary bladder contents’ resi-
dence times were calculated using the OLINDA implementa-
tion of Cloutier’s dynamic bladder model assuming a 4.8 h
void schedule.
The remainder of the body residence time was calculated as
the corrected total body residence time minus all other
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residence times, except urinary bladder and intestines. In this
report, the gastrointestinal tract comprised the small bowel,




The OLINDA/EXM software was used to estimate the
absorbed doses [18]. The OLINDA/EXM software has a
complete series of dosimetry phantoms corresponding to dif-
ferent age “Reference Human” bodies. In this work, the adult
male dosimetry phantom was used exclusively for computing
all absorbed dose estimates. The urinary bladder was assumed
to void regularly at 4.8-h intervals and the gut transit times of
the human adult male were assumed. Kidney absorbed doses
were calculated using the adult male phantom’s default kidney
mass.
The calculation of absorbed dose to salivary glands was
performed using spherical S-values. The S-value is the
absorbed dose per unit cumulated activity and varies inversely
with mass. A table of such S-values [mGy/(MBq-s)] was
calculated from OLINDA/EXM. The S-value for the salivary
gland (77 g) was interpolated from these data. Since the
salivary gland was considered to be a single sphere of 77 g,
the salivary absorbed doses are necessarily conservative. Fur-
ther details are given in Table 1.
Therapy with 131I-MIP-1095
Between July 2011 and June 2012, 28 men with mCRPC who
demonstrated PSMA-avid lesions on imaging received a sin-
gle therapeutic activity of 131I-MIP-1095 (mean activity:
4.8 GBq, range 2.0–7.2 GBq). Post administration, patients
were treated as in-patients on the Nuclear Medicine therapy
ward for 5–7 days according to German radiation protection
laws.
Blood samples were collected from all patients for the
measurement of hematology parameters, GOT, GPT, GGT,
CHE, AP, bilirubin, serum PSA, sodium, potassium, calcium,
phosphate, and thyroid parameters (fT3, fT4, TSH). Thirty
minutes prior to therapy 60 drops of sodium perchlorate
(Irenat®, Bayer, Berlin, Germany) were given. Prior to thera-
py the patients received 1,000 mL of 0,9 %NaCl solution over
1 day (if medically indicated a second NaCl infusion of
1,000 ml was given). The therapy solution was administered
by intravenous infusion over 20 min. In order to reduce
therapy induced damage of the salivary glands, the patients
received lemon juice and ice packs over the parotids and
submandibular glands. On the day of administration, a further
20 drops of sodium perchlorate was given at noon and again in
the evening. In total, the patients received 60 drops per day
(20×3) of sodium perchlorate as well as lemon juice and ice
packs to reduce organ perfusion. A first set of hematology
parameters, liver and kidney values and electrolytes was ac-
quired on day 3–5 after therapy administration. Furthermore,
hematology parameters, liver and kidney values, electrolytes
and serum PSAwere determined on the day of discharge from
the hospital (day 7). Whole body scintigraphy was acquired
on day 6 to 11 (median 7 days, range 6 to 11), and in one case
also at 17 days p.i. The patients were then followed further for
hematology parameters including creatinine, BUN and serum
PSA values. The patient characteristics including previous
therapies are given in supplementary data Table B.
Results
Radiopharmaceuticals
The labeling ofMIPwas performed by radioiododestannylation
of the trimethyltin precursor with either 124I for imaging or 131I
for therapy, respectively, using hydrogen peroxide as the oxi-
dant. Interestingly, no significant dependence of the yields
obtained from the amount of iodide used was observed. The
no-carrier-added radioiodinated PSMA ligands were purified
by solid phase extraction and obtained with high radiochemical
yields after isolation and excellent purities>97%. High specific
activity ranging from 1.5 to 6.4mCi/μmol (55.5 to 236.8MBq /
μmol) could be obtained. Co-injections of the radiolabeled
material with an independently prepared iodinated standard
confirmed the identity of the radioiodinated compounds.
Imaging and pharmacokinetics of 124I-MIP-1095
In addition to the excellent uptake in the prostate tumors and
their metastases, maximum intensity projections of the PET/
CT scans showed high uptake in the salivary glands, often
pronounced in the parotids (Figs. 1 and 2). Focal uptake was
also seen in the lacrimal glands and moderate uptake observed
in the liver and proximal intestine (duodenum and proximal
jejunum). Depending on the time of imaging, the excretion of
the radioactive compound led to visually detectable activity in
the kidneys and the bladder. The uptake in tumor lesions
peaked during the first 24 h after tracer administration. In both
bone and soft tissue tumor lesions the distribution stabilizes at
a high level and only slowly decreases over time (Fig. 2,
Supplementary data Table C).
Dosimetry
The absorbed dose estimates for 124I-MIP-1095 and 131I-MIP-
1095 are listed for each organ in Table 1, and take into account
the voiding time as well as the gut transit time. The organs
receiving the highest absorbed doses following administration
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of 124I-MIP-1095 are the salivary glands with a mean
absorbed dose of 3.8 mSv/MBq, followed by the liver with
1.7 mSv/MBq and the kidneys with 1.4 mSv/MBq.
This leads to an estimated organ absorbed dose for the
administered activities (between 26 and 105 MBq of 124I-
MIP-1095) for the salivary glands of 98–395 mSv. Liver
absorbed doses fall in the range of 43–174 mSv. The kidneys
received an absorbed dose between 36 and 146 mSv. For
estimation of the whole body absorbed dose a mean of
0.42 mSv/MBq was calculated resulting in 11 to 44 mSv
based on our range of injected activities. The effective dose
of 0.59 mSv/MBq accounts for 15 to 62 mSv.
Table 1 Summary of absorbed dose estimates for 124I-PSMA and 131I-PSMA targeted small molecule
Mean SD Min Max Mean SD Min Max
Target Organ mSv/MBq mSv/MBq mSv/MBq mSv/MBq mSv/MBq mSv/MBq mSv/MBq mSv/MBq
Salivary Glands 3.76 2.29 0.28 9.07 4.62 3.10 0.28 11.04
Liver 1.66 0.61 0.66 2.90 1.47 0.70 0.27 2.51
Kidneys 1.39 0.56 0.39 2.43 1.45 0.68 0.50 3.25
LLI Wall 0.98 0.26 0.60 1.50 1.32 1.72 0.18 6.56
Thyroid 0.93 0.99 0.20 3.94 0.91 0.25 0.53 1.39
Spleen 0.77 0.32 0.43 1.65 0.69 0.34 0.32 1.63
ULI Wall 0.70 0.15 0.47 0.95 0.65 0.29 0.28 1.14
Gallbladder Wall 0.69 0.11 0.51 0.91 0.58 0.30 0.23 1.41
Heart Wall 0.61 0.24 0.35 1.16 0.58 0.15 0.33 0.84
UrinaryBladder Wall 0.57 0.10 0.34 0.68 0.51 0.11 0.25 0.64
Adrenals 0.57 0.10 0.43 0.77 0.49 0.13 0.32 0.79
Pancreas 0.56 0.11 0.41 0.78 0.44 0.15 0.24 0.72
Small Intestine 0.52 0.12 0.33 0.71 0.43 0.14 0.25 0.71
Osteogenic Cells 0.51 0.15 0.30 0.74 0.42 0.15 0.21 0.66
Ovaries 0.48 0.12 0.29 0.67 0.42 0.23 0.18 1.11
Lungs 0.47 0.17 0.27 0.90 0.39 0.16 0.18 0.64
Uterus 0.46 0.12 0.29 0.64 0.38 0.16 0.18 0.65
Stomach Wall 0.46 0.11 0.30 0.65 0.38 0.15 0.18 0.62
Thymus 0.38 0.11 0.23 0.56 0.34 0.14 0.16 0.57
Muscle 0.37 0.10 0.23 0.52 0.32 0.14 0.15 0.55
Red Marrow 0.36 0.09 0.23 0.51 0.31 0.14 0.13 0.56
Testes 0.34 0.11 0.19 0.51 0.29 0.12 0.14 0.49
Breasts 0.31 0.08 0.19 0.45 0.29 0.12 0.13 0.48
Skin 0.28 0.08 0.17 0.39 0.27 0.12 0.12 0.47
Brain 0.13 0.03 0.07 0.18 0.10 0.03 0.04 0.15
Total Body 0.42 0.09 0.28 0.58 0.37 0.13 0.20 0.62
Effective Dose Equivalent (mSv/MBq) 0.65 0.12 0.47 0.89 0.60 0.15 0.41 0.99
Effective Dose (mSv/MBq) 0.58 0.11 0.41 0.78 0.54 0.14 0.35 0.84
ULI wall upper large intestinal wall. LLI wall lower large intestinal wall 124 I-PSMA 131 I-PSMA
Fig. 1 124I-MIP-1095 PET
images (maximal intensity
projection) of patient 01 as a
function of time
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Based on the biodistribution data obtained from the 124I-
MIP-1095 PET images, we calculated the absorbed dose for
131I-MIP-1095 using the physical decay characteristics of 131I.
Based on this extrapolation and the biomodeling obtained
from the 124I-MIP-1095 PET images, the organs receiving
the highest absorbed doses following administration of 131I-
MIP-1095 are the salivary glands (mean dose 4.6 mSv/MBq,
followed by the liver (1.5 mSv/MBq) and the kidneys
(1.5 mSv/MBq).
This leads to an estimated absorbed dose for the injected
therapy activities (mean dose: 4.8 GBq, range 2.0–7.2 GBq)
for the salivary glands of 9.2 to 33.3 Sv. Liver radiation doses
fall in the range of 2.9 to 10.6 Sv. The kidneys received a total
absorbed dose between 2.9 and 10.4 Sv. The mean, total
whole body absorbed dose was 0.38 mSv/MBq resulting in
0.76 to 2.7 Sv based on our injected activities.
These data were compared to the dosimetric values report-
ed for the 90Y- and 177Lu-labeled antibody J591 (Supplemen-
tary data Table D) [9, 10]. The ratio 131I-MIP-1095 to 90Y-
J591 or 177Lu-J591 showed that the absorbed doses for 131I-
MIP-1095 were markedly lower than for the 90Y-labeled
antibody. Compared to the 177Lu-labeled antibody the effec-
tive dose obtained with 131I-MIP-1095 is higher, red marrow
and kidney doses are similar and the liver dose is lower.
Therapy with 131I-MIP-1095
We treated 28 patients with 131I-MIP-1095. Three patients
were lost to follow up. Serum PSA values were available for
25 patients and hematologic data for 24 patients. In all patients
the tracer was taken up avidly in tumor lesions and remained
in these lesions for a prolonged period of time. Figure 3 shows
an example where the lesions were visible even 17 days after
administration of 131I-MIP-1095.
Side effects and toxicity
A summary of the available medical history, demographics,
treatment history, imaging studies, and 131I-MIP-1095 treat-
ment activities, and general comments can be found in sup-
plementary data Table B.
In 14 patients WBC counts fell below the normal range
after therapy (10 patients with grade 1, 3 with grade 2 and one
with grade 3 toxicity). However, five of these 14 patients had
levels below normal prior to therapy (four grade 1, one with
grade 2). Erythrocytes counts fell below the normal range at
nadir in 21 patients with 17 patients having lower values prior
to therapy. With respect to platelets, 11 patients had a reduc-
tion in counts below normal after therapy (eight grade 1, one
grade 2 and two grade 3), one having had a value below
normal (grade 2) prior to therapy (Fig. 4). The changes in
hematological parameters were not related to the activity
administered (Supplementary Table E).
Because of physiological PSMA expression in the kidneys
there is concern regarding the potential for radiation toxicity to
the kidneys as a possible chronic long-term side effect of
PSMA targeted endoradiotherapies. Available clinical data
were collected to assess renal function. While the data are
inherently limited in terms of long-term follow-up, as the post-
Fig. 2 Average SUVs for normal organs (a and b) and tumor (c). Mean
tumor SUVs are determined from 110 individual lesions in 16 patients
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treatment interval of most of these patients provides less than a
year of follow-up, there is no apparent evidence or negative
trend in either calculated GFR or serum creatinine levels. The
parameters describing kidney function were largely un-
changed: GFR decreased below normal in one patient, im-
proved from below normal to within the normal range in two
patients and remained stable below normal in one patient
(Fig. 5a). All creatinine levels were in the normal range prior
to treatment and remained in the normal range post treatment
(Fig. 5b). BUN values were largely unchanged with three
patients above normal values after therapy (grade 1) and six
patients (grade 1) prior to therapy (Fig. 5c). These findings are
consistent with the estimated absorbed doses to the kidney
which were significantly below 23 Gy. The evaluation of liver
function tests and thyroid hormone revealed no change of
these parameters after therapy (data not shown).
In some patients, evidence of non-hematological transient
side effects was found: seven patients reported having a slight
to moderate xerostomia, and in one patient mucositis was
detected. All reported side effects recovered after 3 to 4 weeks.
This latter finding is likely due to the high level of radiophar-
maceutical accumulation in these organs and the estimated
absorbed doses.
Response
All 28 patients had progressive metastatic hormone refractory
disease by serum PSA, radiographic or clinical measures.
Thirteen patients complained of bone pain related to their
metastases prior to treatment with 131I-MIP-1095. After treat-
ment, three out of 13 (23.1 %) patients had reported complete
resolution of bone pain and eight (61.5 %) reported a decrease
in pain severity. In the remaining two patients, the outcome is
unknown.
Overall best PSA response after a single cycle of 131I-MIP-
1095 is provided in Fig. 6a. In 60.7 % of patients, a decline in
serum PSA levels of ≥50 % was observed; seven (25 %) had
more than a 75 % drop in PSA, 10 (35.7 %) had a drop
between 50 and 75 %, two (7.1 %) between 25 % and 50 %
and two (7.1 %) between 0 and 25 % (Fig. 6). One patient
showed a long lasting complete response by serum PSAvalue
and by radiographic imaging (Fig. 7). In four patients, an
increase of PSA was observed. As with the hematological
parameters, also the changes in PSA value were not related
to the activity administered (Fig. 6b). In the 19 patients show-
ing a more than 25% decrease in PSA the median time to PSA
progression was 126 days (range 62 to 469 days; Fig. 6c). A
decrease in PSA was associated with a decrease in number
and/or intensity of the lesions visualized on the post-
therapeutic PET/CT scan with 68Ga-labeled Glu-NH-CO-
NH-Lys(Ahx)-HBED-CC. Figure 8 shows two patients with
a dramatic reduction of tracer uptake in the tumor lesions after
one cycle of PSMA treatment.
Discussion
PET imaging with 124I-MIP-1095 showed rapid uptake and
long lasting accumulation in prostate cancer metastases with
significantly lower uptake in most normal tissues except for
parotid and salivary glands, leading to high tumor contrast
(Figs. 1 and 2). We have shown that 131I-MIP-1095 displays
rapid and high uptake and prolonged retention in tumor le-
sions and that 124I-MIP-1095 can be used to confirm PSMA-
avidity and estimate normal organ dosimetry prior to
Fig. 3 Anterior and posterior whole body scintigrams of 131I-MIP-1095 in patient 01 at 7, 10 and 17 days post injection
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treatment. These findings are consistent with previous reports
of tumor uptake and retention using 123I-MIP-1095 in men
with mCRPC [19] and extend our understanding of the tumor
and normal tissue kinetics due to the longer half-lives of the
radioiodine isotopes 124I and 131I. This distribution pattern of
the tracer fits the PSMA expression profile previously report-
ed for prostate cancer metastases and normal tissues [20–22].
The main elimination process is the renal system, although
uptake by the salivary glands and the intestines might suggest
also gastrointestinal action. However, we found that the pa-
rotids showed a prolonged retention of the radioiodinated
PSMA-targeted ligands that even led, in some cases, to an
intensified uptake after about 20 h (Fig. 2). This suggests that
a forced excretion might not show an effect on the uptake in
Fig. 4 Hematological data for all patients prior to and after treatment;
leukocytes (a), erythrocytes (b) and platelets (c). Solid red lines indicate
range or normal limit
Fig. 5 Renal function tests for all patients prior to and after therapy;
GFR,measuredwith 99mTc-MAG3 scintigraphy (a), Serum creatinine (b),
Blood urea nitrogen (c). Solid red lines indicate range or normal limit
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the salivary glands. The uptake in the proximal small intestine
is explained by natural occurrence of PSMA in this organ [21].
Calculations of mean radiation absorbed doses for 131I-
MIP-1095 based on the pharmacokinetic data derived from
the 124I-MIP-1095 PET scan images indicate that the normal
tissues with the highest absorbed doses are salivary glands,
liver, kidney and lower large intestine, respectively (Table 1).
A comparison of the dosimetric values for 131I-MIP-1095 with
the data published for the 90Y- and 177Lu-labeled J591 anti-
body [9, 10] revealed favorable results for the small molecule
when compared to the 90Y-labeled antibody. A comparison
with the 177Lu-labeled antibody revealed a higher effective
dose, a lower liver dose and similar values for bone marrow
and kidneys.
According to the dosimetric data salivary glands, liver,
kidney and lower large intestine represent potential concern
for side effects. Since many endoradiotherapeutic procedures
are associated with hematological toxicity we also evaluated
the effects of therapy on leucocytes, erythrocytes and platelets.
We observed changes in hematological profiles in most pa-
tients after therapy, albeit many of these individuals had
subnormal values at baseline. This is most probably due to
previous systemic therapy affecting the bone marrow, which
can be expected for the present patient population. Almost all
of these patients had multiple therapies before 131I-MIP-1095
including chemotherapy in many cases (Supplementary data
Table B). The onset of myelosuppression occurred within
6 weeks post treatment with quite variable time to recovery,
in some cases requiring up to 3–6 months for recovery. White
blood cells typically recovered within several weeks, while
platelets required several months to recover.
No significant changes in renal function were noted across
patients after treatment (Fig. 5). Based on normal tissue toler-
ance limits for external beam radiotherapy as described by
Emami et al. [23], these absorbed dose estimates suggest that
administered activities of up to 15 GBq (428 mCi) can be
given based on kidney absorbed dose limits of 23 Gy. How-
ever, this value was derived from external beam radiotherapy
and does not predict renal toxicity associated with
radiotherapeutics. Correction of these data for patient-
specific organ volume, adjustment or the linear-quadratic dose
rate effect and expression in terms of biologic effective dose
(BED) finally delivered values correlating with renal toxicity.
With these methods, a total limit not to exceed 37 Gy BED to
the kidneys has been proposed (for a detailed discussion and
data obtained, see Supplementary information and Supple-
mentary Table F). The maximum administered activity given
in a single administration to stay below 37 Gy BED to the
kidneys in our patients would range from 298 mCi to
1092 mCi (11 to 40 GBq) with a mean value of 668 mCi
(24.7 GBq) as listed in Table 2 of the Supplementary infor-
mation. With regard to a future dose escalation study, it has to
be stated that a 2 mCi/kg (LBM) starting dose for the first
cohort is at the lower end of the range of administered activity
in our patients (Table 1 of Supplementary information) and
provides room for a reasonable escalation of the subsequent
cohorts and/or multiple doses of 131I-MIP-1095. Furthermore,
Fig. 6 Effects of PSMA ligand therapy on PSA values. aWaterfall plot
of best PSA response, compared to baseline, after a single cycle of 131I-
MIP-1095; b Relation of change in PSA to the activity given and c
Relation of the time to PSA progression to the activity given
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liver function and thyroid hormone values did not change after
treatment.
The intense accumulation of 131I-MIP-1095 in the salivary
and parotid glands suggest that these glands may likely be
Fig. 7 Patient 04. a Pre-therapy 124I-MIP-1095 PET scans (top) and CT
scan (bottom). b Pre-therapy SUV values for LN metastasis, recurrent
tumor, submandibular salivary glands and parotid glands as a function of
time. c Serum PSA values as a function of time from treatment. d Post-
therapy Glu-NH-CO-NH-Lys(Ahx)-[68Ga]-HBED-CC PET scan (top)
and CT scan (bottom)
Fig. 8 Two patients (a, b and c, d)
prior (a, c) and after (b, d) therapy
showing reduced tracer
accumulation in their tumor
lesions after treatment
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affected by therapy. Seven patients have reported dry mouth
and one patient was reported to have mucositis. These symp-
toms were transient in nature and resolved 3 to 4 weeks after
treatment. However, we cannot exclude that these symptoms
will be accentuated or evenmay not recover whenmore cycles
are given. We attempted to reduce the uptake of the radio-
pharmaceutical by the glands by use of cold packs and lemon
juice. It is not clear what, if any, impact these prophylactic
measures had on an individual patient’s glandular function,
and further clinical investigation is needed. Since PSMA is
expressed constitutively in the salivary glands, the tracer binds
to this target and it is rather improbable that lemon juice will
have an impact on the local absorbed dose. This may include
attempts at displacement of the tracer from the salivary glands
by administration of the unlabeled compound or competing
alternative PSMA inhibitors after peak tumor uptake has been
reached. Since, in tumors, the ligands are internalized after
binding, this displacement strategy should not influence tumor
accumulation or retention. However, it is not clear yet whether
the PSMA ligands are handled differently in normal organs
such as salivary glands or kidneys than in tumors.
Administration of therapeutic activities of 131I-MIP-1095
demonstrated high levels of tumor uptake and prolonged
retention as noted in Fig. 3. This is a prerequisite for a
successful therapeutic application. Therapeutic efficacy was
demonstrated (1) by symptom relief and (2) by a decrease in
PSA values: out of 13 patients with bone pain, three patients
had no pain and eight had a decrease in pain severity after
therapy. For two patients no information was available. With
regard to the PSA values 61 % had a decline of 50 % or more
whereas 75 % had a drop off 30 % or greater (Fig. 6). One
patient showed a long lasting complete response (Fig. 7).
These effects on PSA were not related to the activity given
to the patients, indicating that several biological features are
influencing therapeutic efficacy such as differences in repair
mechanisms in different metastases and varying protecting
factors excreted from bone marrow nearby of bone metasta-
ses. Since the patients in this evaluation were mostly present-
ing with a huge tumor burden, relapse of the disease was
expected. The median time to PSA progression was 126 days,
indicating that multiple therapy cycles may be necessary to
obtain a long lasting response. However, this may be associ-
ated with more pronounced side effects, especially concerning
the salivary glands. Bear in mind that most of these patients
will have chemotherapy before we may expect that the pre-
damaged bone marrow will be the dose-limiting organ in a
considerable number of patients. This problem is shown by
the data presented in Fig. 4: 17 of 21 patients had erythrocyte
values below normal before therapy.
In general, we observed that lymph node metastases
showed a better response than bone metastases, but the num-
ber of patients with lymph nodemetastases only was too small
(only two patients, Figs. 7 and 8c, d) to draw a conclusion on
that matter. Since bone metastases from prostate cancer are
usually osteoblastic we may expect absorption of the beta
particles leading to a reduced cross-fire effect in these lesions.
Furthermore, as mentioned above, protective factors may be
secreted by the surrounding bone or bone marrow.
Conclusion
The systemic therapy with cytotoxic drugs causes side effects
in the proliferating organs and it is anticipated that targeted
drugs are free of these effects. However, targeted drugs may
have the side effects seen in the excreting organs and in off-
target organs with expression of the target. Moreover, when
treating the enormous masses of tumor tissue found in the
otherwise incurable patients, collective activities that threaten
other organs have to be applied. Consequently, dosimetric
studies are imperative prior to the application of novel targeted
endoradiotherapeutic drugs.
The preliminary findings presented here of 28 patients with
late-stage hormone- and chemotherapy-refractory prostate
cancer after PSMA-targeted systemic radiotherapy are encour-
aging. In most cases there was extensive skeletal and soft
tissue involvement of their cancer and most patients were
clinically anemic at the time of treatment due to the stage of
their disease and treatments they had endured.
To date, the results of both the 124I diagnostic and 131I
therapeutic administration have shown that the treatment was
well-tolerated, allowing for the estimation of absorbed dose to
normal organs, and the patients demonstrated objective clinical
measures of improvement in their condition. Preliminary effi-
cacy was demonstrated by PSA reduction, a general observa-
tion of a reduction in bone pain and improved quality of life,
and radiographic reductions in disease burden as evidenced by
reduction in lesion size, extent and number of lesions as seen
on the diagnostic scans. This has to be compared to the efficacy
obtained with carbazitaxel [24], the current gold standard for
the treatment of mCRPC. The limited efficacy of this com-
pound, together with its strong side effects can be explained as
it is known that taxanes, similar to other, non-targeted cytotox-
ic drugs do not show specific uptake [25].
Additional acute toxicities that were felt to be treatment-
related included radiation-induced xerostomia and one case of
hypothyroidism in a patient who experienced nausea and
emesis after receiving the thyroid blocking agent prior to
treatment. Because of the concern regarding the potential for
radiation toxicity to the kidneys as a possible chronic long-
term side effect of 131I-MIP-1095 therapy, available clinical
data were collected that assessed renal function. While the
data are inherently limited in terms of long-term follow-up, as
the treatment of most of these patients provides less than a
year of follow-up, there is no apparent evidence or negative
trend in either calculated GFR or serum creatinine levels,
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which is consistent with the absorbed dose estimates to
kidneys.
Overall, the patients tolerated the PSMA-targeted molecule
treatments well. Myelosuppression was the primary and most
significant side effect and was seen in most of the patients,
varying in degree from mild to moderate. However, these
patients had multiple treatments including chemotherapy be-
fore and many presented with values below normal already at
baseline.
It has to be emphasized that, in our view, most patients
preferred this form of treatment over chemotherapy to help
control their disease. Most patients have reported a reduction
in bone pain and an improved quality of life and mental state
since receiving the PSMA-targeted molecule therapy. These
encouraging preliminary results warrant the formal evaluation
of the 131I-labeled small molecule inhibitor of PSMA in
controlled clinical studies.
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